Compare Stocks: ANRO, INDV, OGN, and ARQT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$27.48 -10.7%	$31.21	$3.77 ▼ $37.48	$1.21B	1.13	505,598 shs	639,852 shs
ARQT Arcutis Biotherapeutics	$26.38 -5.0%	$25.83	$16.57 ▼ $31.77	$3.49B	1.5	3.20 million shs	2.51 million shs
INDV Indivior	$35.91 -0.8%	$37.31	$22.56 ▼ $42.81	$4.27B	0.82	2.02 million shs	1.06 million shs
OGN Organon & Co.	$13.74 +0.3%	$13.66	$5.69 ▼ $13.78	$3.60B	1.52	2.93 million shs	983,335 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-10.78%	-8.56%	-24.55%	+8.86%	+571.74%
ARQT Arcutis Biotherapeutics	-5.04%	+0.92%	+6.46%	-1.16%	+49.89%
INDV Indivior	-0.77%	+4.54%	-0.75%	-13.03%	+54.85%
OGN Organon & Co.	+0.15%	+0.44%	-0.14%	+1.93%	+30.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$27.48 -10.7%	$31.21	$3.77 ▼ $37.48	$1.21B	1.13	505,598 shs	639,852 shs
ARQT Arcutis Biotherapeutics	$26.38 -5.0%	$25.83	$16.57 ▼ $31.77	$3.49B	1.5	3.20 million shs	2.51 million shs
INDV Indivior	$35.91 -0.8%	$37.31	$22.56 ▼ $42.81	$4.27B	0.82	2.02 million shs	1.06 million shs
OGN Organon & Co.	$13.74 +0.3%	$13.66	$5.69 ▼ $13.78	$3.60B	1.52	2.93 million shs	983,335 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-10.78%	-8.56%	-24.55%	+8.86%	+571.74%
ARQT Arcutis Biotherapeutics	-5.04%	+0.92%	+6.46%	-1.16%	+49.89%
INDV Indivior	-0.77%	+4.54%	-0.75%	-13.03%	+54.85%
OGN Organon & Co.	+0.15%	+0.44%	-0.14%	+1.93%	+30.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.25	35.55% Upside
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	34.84% Upside
INDV Indivior	2.86	Moderate Buy	$45.17	25.78% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.00% Downside

Current Analyst Ratings Breakdown

Latest ANRO, INDV, OGN, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/4/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	ANRO Alto Neuroscience	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
8/13/2026	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$24.00 ➝ $26.00
8/13/2026	ANRO Alto Neuroscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $37.00
8/7/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/6/2026	ARQT Arcutis Biotherapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$34.00 ➝ $38.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
ARQT Arcutis Biotherapeutics	$463.98M	7.15	N/A	N/A	$1.55 per share	17.02
INDV Indivior	$1.24B	3.42	$2.70 per share	13.31	($0.78) per share	-46.04
OGN Organon & Co.	$6.22B	0.58	$5.80 per share	2.37	$2.89 per share	4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	125.63	23.14	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
INDV Indivior	$210M	$2.79	12.87	9.38	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.84	3.99	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)

Latest ANRO, INDV, OGN, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A

Latest ANRO, INDV, OGN, and ARQT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/17/2026	INDV Indivior	special	$8.13		10/30/2026	10/30/2026	11/6/2026
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
INDV Indivior	N/A	0.84	0.66
OGN Organon & Co.	8.43	1.95	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
ARQT Arcutis Biotherapeutics	N/A
INDV Indivior	60.33%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
ARQT Arcutis Biotherapeutics	9.40%
INDV Indivior	0.74%
OGN Organon & Co.	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	68	39.24 million	34.83 million	N/A
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
INDV Indivior	838	118.03 million	117.16 million	Not Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable

ANRO, INDV, OGN, and ARQT Headlines

Recent News About These Companies

Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts

September 23 at 3:16 AM | americanbankingnews.com

September 21 at 10:01 AM | zacks.com

Organon & Co. (NYSE:OGN) Given Consensus Recommendation of "Reduce" by Brokerages

September 18, 2026 | marketbeat.com

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

September 14, 2026 | businesswire.com

Organon & Co. $OGN Position Cut by Squarepoint Ops LLC

September 12, 2026 | marketbeat.com

Organon: A Merger-Arbitrage Hold With Limited Upside

September 12, 2026 | seekingalpha.com

Orogen Royalties Acquires the Serpent Gold Project in Nevada

September 10, 2026 | accessnewswire.comA

WINTON GROUP Ltd Invests $6.90 Million in Organon & Co. $OGN

September 10, 2026 | marketbeat.com

434,200 Shares in Organon & Co. $OGN Acquired by Maven Securities LTD

September 9, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Position in Organon & Co. $OGN

September 9, 2026 | marketbeat.com

Carmignac Gestion Purchases Shares of 448,606 Organon & Co. $OGN

September 8, 2026 | marketbeat.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

September 8, 2026 | zacks.com

Organon & Co. (NYSE:OGN) Hits New 12-Month High - Should You Buy?

September 8, 2026 | marketbeat.com

Readystate Asset Management LP Makes New Investment in Organon & Co. $OGN

September 7, 2026 | marketbeat.com

Groupe la Francaise Acquires Shares of 775,382 Organon & Co. $OGN

September 7, 2026 | marketbeat.com

Absolute Gestao de Investimentos Ltda. Takes Position in Organon & Co. $OGN

September 7, 2026 | marketbeat.com

Organon & Co. (OGN) Stock Price, News, Quote & History - Yahoo Finance

September 4, 2026 | finance.yahoo.com

Organon & Co. (OGN) Stock Earnings Call Transcripts - Yahoo Finance

September 1, 2026 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Hits New 52-Week High - Should You Buy?

August 31, 2026 | marketbeat.com

Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN

August 29, 2026 | marketbeat.com

2,670,523 Shares in Organon & Co. $OGN Bought by Kahn Brothers Group Inc.

August 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, INDV, OGN, and ARQT Company Descriptions

Alto Neuroscience NYSE:ANRO

$27.48 -3.30 (-10.72%)

Closing price 09/23/2026 03:59 PM Eastern

Extended Trading

$27.65 +0.17 (+0.61%)

As of 07:19 AM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Arcutis Biotherapeutics NASDAQ:ARQT

$26.38 -1.40 (-5.04%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$26.20 -0.18 (-0.68%)

As of 07:29 AM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Indivior NASDAQ:INDV

$35.91 -0.28 (-0.77%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$35.54 -0.37 (-1.03%)

As of 07:04 AM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organon & Co. NYSE:OGN

$13.74 +0.04 (+0.26%)

Closing price 09/23/2026 03:59 PM Eastern

Extended Trading

$13.72 -0.01 (-0.07%)

As of 07:40 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANRO, INDV, OGN, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANRO, INDV, OGN, and ARQT Earnings

Compare Dividends

Latest ANRO, INDV, OGN, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANRO, INDV, OGN, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, INDV, OGN, and ARQT Company Descriptions

Alto Neuroscience NYSE:ANRO

Arcutis Biotherapeutics NASDAQ:ARQT

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANRO, INDV, OGN, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANRO, INDV, OGN, and ARQT Earnings

Compare Dividends

Latest ANRO, INDV, OGN, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANRO, INDV, OGN, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, INDV, OGN, and ARQT Company Descriptions

Alto Neuroscience NYSE:ANRO

Arcutis Biotherapeutics NASDAQ:ARQT

Indivior NASDAQ:INDV

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools